Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines.
Spectral karyotyping (SKY) and comparative genomic hybridization (CGH) have greatly enhanced the resolution of cytogenetic analysis, enabling the identification of novel regions of rearrangement and amplification in tumor cells. Here we report the analysis of 10 malignant non-Hodgkin lymphoma (NHL) cell lines derived at the Ontario Cancer Institute (OCI), Toronto, designated as OCI-Ly1, OCI-Ly2, OCI-Ly3, OCI-LY4, OCI-Ly7, OCI-Ly8, OCI-Ly12, OCI-Ly13.2, OCI-Ly17, and OCI-Ly18, by G-banding, SKY, and CGH, and we present their comprehensive cytogenetic profiles. In contrast to the 52 breakpoints identified by G-banding, SKY identified 87 breakpoints, which clustered at 1q21, 7p15, 8p11, 13q21, 13q32, 14q32, 17q11, and 18q21. G-banding identified 10 translocations, including the previously described recurring translocations, t(8;14)(q24;q32) and t(14;18)(q32;q21). In contrast, SKY identified 60 translocations, including five that were recurring, t(8;14)(q24;q32), t(14;18)(q32;q21), t(4;7)(p12;q22), t(11;18)(q22;q21), and t(3;18)(q21;p11). SKY also identified the source of all the marker chromosomes. In addition, 10 chromosomes that were classified as normal by G-banding were found by SKY to be rearranged. CGH identified seven sites of high-level DNA amplification, 1q31-32, 2p12-16, 8q24, 11q23-25, 13q21-22, 13q32-34, and 18q21-23; of these, 1q31-32, 11q23-25, 13q21-22, and 13q32-34 have previously not been described as amplified in NHL. This comprehensive cytogenetic characterization of 10 NHL cell lines identified novel sites of rearrangement and amplification; it also enhances their value in experimental studies aimed at gene discovery and gene function.
Mehra
Sukvarsha
S
Laboratory of Cancer Genetics, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Messner
Hans
H
Minden
Mark
M
Chaganti
R S K
RS
D002869:Chromosome Aberrations; D002871:Chromosome Banding / Q000379:methods; D020732:Cytogenetic Analysis / Q000379:methods*; D005260:Female; D006801:Humans; D007621:Karyotyping / Q000379:methods; D016393:Lymphoma, B-Cell / Q000235:genetics; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics*; D016399:Lymphoma, T-Cell / Q000235:genetics; D008297:Male; D009693:Nucleic Acid Hybridization; D014407:Tumor Cells, Cultured